TRX — Tissue Regenix Income Statement
0.000.00%
Last trade - 00:00
- £43.40m
- £46.60m
- $29.49m
- 48
- 21
- 82
- 47
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 16.6 | 16.4 | 19.7 | 24.5 | 29.5 |
Cost of Revenue | |||||
Gross Profit | 7.68 | 7.56 | 8.48 | 11.3 | 14 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 25.8 | 29 | 24.2 | 26.5 | 29.9 |
Operating Profit | -9.19 | -12.6 | -4.45 | -2.01 | -0.394 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.77 | -13.1 | -5.14 | -2.83 | -1.67 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.07 | -12.4 | -4.99 | -2.6 | -1.66 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -8.9 | -12.4 | -4.79 | -2.69 | -1.71 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.9 | -12.4 | -4.79 | -2.69 | -1.71 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.758 | -0.174 | -0.065 | -0.038 | -0.024 |
Dividends per Share |